Tongfu, China (01763): Affiliated to Beijing Normal University signed a patent transfer agreement for an innovative nuclear drug such as fluorine [18F] betasine and an industry-university-research project cooperation agreement

^{Zhitong Finance App News, China Tongpo (01763) announced that on December 10, 2025, Atomic Hi-Tech Co., Ltd. (a subsidiary of the company listed on the National SME Share Transfer System) and Beijing Normal University held a scientific and technological achievement transformation signing and industry-university-research cooperation exchange meeting in Beijing, and jointly signed the “Patent Transfer Agreement” and “Industry-University-Research Cooperation Agreement” for the fluorine [18F] betazine project.}

Fluorine [^18F] betazine is the result of collaboration between Professor Cui Mengchao's team at Beijing Normal University and Atomic Technology. It is a new type of drug with completely independent intellectual property rights, and is mainly used for early diagnosis of Alzheimer's disease. In clinical application, the drug showed a significant reduction in non-specific brain white matter uptake, which is superior to similar products that have been approved by the FDA.

The signing of this agreement is not only a phased summary of the results of early cooperation between the two sides, but also a key starting point for universities and enterprises to work together to transform scientific research results into the country's strategic productivity. Currently, the nuclear medicine industry is entering a golden period of development. With deep industry accumulation and distinctive industrial characteristics, Atom Hi-Tech has become the core force in the field. In the future, the two sides will use industry-university-research collaboration as a link to accelerate the clinical transformation of core achievements, build a fast track for talent co-development, participate in global nuclear drug technology competition, and lay a solid foundation for the high-quality development of China's nuclear medicine industry.